Twist Bioscience (NASDAQ:TWST) Stock Price Down 4.8% – Time to Sell?

Posted by Geri Gentry on Nov 13th, 2026

Twist Bioscience Corporation (NASDAQ:TWST – Get Free Report)’s share price traded down 4.8% during trading on Wednesday. The stock traded as low as $125.01 and last traded at $125.7850. 1,776,661 shares were traded during trading, an increase of 1% from the average session volume of 1,764,008 shares. The stock had previously closed at $132.13.

Key Headlines Impacting Twist Bioscience

Here are a few of the latest headlines about TWST:

Positive Sentiment: Fiscal Q4 revenue rose 28% year over year to $126.6 million, topping the $123.55 million consensus. The loss of $0.32 per share was also narrower than analysts’ expected $0.39 loss. AI drug discovery generated $59.1 million in fiscal 2026 revenue. Twist Bioscience: 3 Key Takeaways for Long-Term Investors
Positive Sentiment: Fiscal Q1 2027 revenue guidance of $130 million–$132 million exceeded the $126.3 million consensus. Full-year revenue guidance of $550 million–$560 million was modestly above the $549 million estimate. Fiscal 2026 results and guidance
Negative Sentiment: Despite the earnings and revenue beats, coverage characterized the fiscal 2027 outlook as underwhelming, suggesting the guidance did not satisfy investor expectations. That concern appears to have outweighed the strong quarter and contributed to selling pressure. Twist Bioscience stock slips despite Q4 beat

Analysts Set New Price Targets

TWST has been the subject of several research analyst reports. Piper Sandler lifted their target price on shares of Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, August 5th. Canaccord Genuity Group lowered their price objective on shares of Twist Bioscience from $205.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday. Guggenheim lifted their price objective on shares of Twist Bioscience from $107.00 to $212.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Robert W. Baird reduced their target price on Twist Bioscience from $187.00 to $135.00 and set an “outperform” rating on the stock in a research note on Friday. Finally, UBS Group began coverage on Twist Bioscience in a research report on Wednesday, September 9th. They set a “neutral” rating and a $144.00 price target on the stock. Seven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Twist Bioscience presently has an average rating of “Hold” and an average price target of $145.00.

Check Out Our Latest Analysis on Twist Bioscience

Twist Bioscience Stock Performance

The company has a market cap of $7.12 billion, a PE ratio of -51.22 and a beta of 2.25. The business’s 50-day moving average is $150.57 and its 200 day moving average is $92.73. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%. The firm had revenue of $126.64 million for the quarter, compared to analysts’ expectations of $123.55 million. Twist Bioscience’s revenue for the quarter was up 26.7% compared to the same quarter last year. On average, equities research analysts predict that Twist Bioscience Corporation will post -2.11 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Emily Leproust sold 4,573 shares of the business’s stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $135.40, for a total transaction of $619,184.20. Following the transaction, the chief executive officer owned 558,187 shares in the company, valued at $75,578,519.80. The trade was a 0.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Dennis Cho sold 949 shares of the company’s stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $135.40, for a total value of $128,494.60. Following the transaction, the insider directly owned 62,840 shares of the company’s stock, valued at $8,508,536. The trade was a 1.49% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 495,279 shares of company stock worth $80,489,387. 3.08% of the stock is currently owned by insiders.

Institutional Trading of Twist Bioscience

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Abacus Wealth Partners LLC lifted its position in shares of Twist Bioscience by 4.3% in the 3rd quarter. Abacus Wealth Partners LLC now owns 2,332 shares of the company’s stock worth $451,000 after purchasing an additional 96 shares during the period. Root Financial Partners LLC purchased a new position in shares of Twist Bioscience during the third quarter valued at about $33,000. GAMMA Investing LLC lifted its holdings in Twist Bioscience by 24.4% in the second quarter. GAMMA Investing LLC now owns 943 shares of the company’s stock worth $97,000 after buying an additional 185 shares during the period. Abel Hall LLC boosted its position in Twist Bioscience by 3.6% during the 3rd quarter. Abel Hall LLC now owns 5,514 shares of the company’s stock valued at $1,066,000 after acquiring an additional 191 shares in the last quarter. Finally, Allworth Financial LP boosted its position in Twist Bioscience by 54.9% during the 2nd quarter. Allworth Financial LP now owns 601 shares of the company’s stock valued at $62,000 after acquiring an additional 213 shares in the last quarter.

Twist Bioscience Company Profile

(Get Free Report)

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.